ValiRx plc (LON:VAL – Get Free Report) shares hit a new 52-week low during trading on Tuesday . The company traded as low as GBX 1.21 ($0.02) and last traded at GBX 1.21 ($0.02), with a volume of 227160 shares traded. The stock had previously closed at GBX 1.25 ($0.02).
ValiRx Price Performance
The company has a debt-to-equity ratio of 0.49, a current ratio of 6.65 and a quick ratio of 1.27. The company has a market cap of £1.65 million, a PE ratio of -60.65 and a beta of 0.59. The company has a 50-day moving average price of GBX 1.91 and a two-hundred day moving average price of GBX 2.60.
About ValiRx
ValiRx plc, a biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company's lead drug candidates include VAL201, a short peptide that has completed Phase I/II trials for the treatment of prostate cancer; and VAL401, a reformulation of anti-psychotic drug risperidone, which has completed Phase II clinical trial for the treatment of end-stage non-small cell lung cancer.
Featured Articles
- Five stocks we like better than ValiRx
- How to Use the MarketBeat Stock Screener
- Taiwan Semiconductor Soars on Earnings With More Room to Run
- The 3 Best Fintech Stocks to Buy Now
- Is Lucid Group Nearing the Bottom? What Investors Should Know
- Basic Materials Stocks Investing
- 90% Gain Possible? Analysts Are Bullish on Joby Aviation
Receive News & Ratings for ValiRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ValiRx and related companies with MarketBeat.com's FREE daily email newsletter.